(Albany, USA) DelveInsight's "Osteoarthritis Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Osteoarthritis, historical and forecasted epidemiology as well as the Osteoarthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Osteoarthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Osteoarthritis market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Osteoarthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Osteoarthritis market.
Request for a Free Sample Report @ Osteoarthritis Market Forecast
Some facts of the Osteoarthritis Market Report are:
- According to DelveInsight, Osteoarthritis market size is expected to grow at a decent CAGR by 2034.
- In 2023, the osteoarthritis US market size was approximately USD 19,000 million, which is further expected to increase by 2034.
- Leading Osteoarthritis companies working in the market are Novartis, Ampio Pharmaceuticals, Taiwan Liposome Company, Centrexion Therapeutics, Biosplice Therapeutics, Organogenesis, Kolon Tissuegene, Paradigm Biopharma, Novo Nordisk, Amzell, Nature Cell, Tissuetech, Techfields Pharma, Sorrento Therapeutics, Merck Kgaa, Anika Therapeutics, Trialspark, Akl Research And Development, Flexion Therapeutics, OliPass Corporation, Pacira BioSciences, Medipost, Medivir, and others.
- Key Osteoarthritis Therapies expected to launch in the market are ZILRETTA, CINGAL, TRIVISC, VISCO-3, LNA043, ReNu (Amniotic Suspension Allograft), JointStem, CNTX-4975, and others.
- In February 2025, Zydus Lifesciences (NSE: ZYDUSLIFE) received final approval from the U.S. Food and Drug Administration (FDA) to produce Ibuprofen and Famotidine tablets (800 mg/26.6 mg), marketed under the brand name Duexis. This drug combination is indicated for the management of symptoms associated with rheumatoid arthritis and osteoarthritis, while also minimizing the risk of upper gastrointestinal ulcers in patients taking ibuprofen for these conditions.
- Also in February 2025, Aurora Pharmaceutical (Private) introduced EquiCoxib, its FDA-approved generic version of Equioxx® (firocoxib)—a non-steroidal anti-inflammatory drug (NSAID) designed to relieve pain and inflammation due to osteoarthritis
- On November 12, 2024, Genascence Corporation (Private)—a clinical-stage biotech company specializing in gene therapy for musculoskeletal disorders—announced that the FDA has granted Fast Track Designation (FTD) to GNSC-001, a novel gene therapy candidate currently under development for treating knee osteoarthritis.
- In December 2023, Bioventus agreed to a nationwide contract with Aetna Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis pain.
- In December 2023, Levicept announced that it had completed recruitment in its Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent. Top-line data are expected to be announced in the late first half of 2024.
- In Jan 2023, OliPass Corporation announced a study which is designed to evaluate the efficacy, safety and tolerability of OLP-1002 Subcutaneous (SC) injections for reducing moderate to severe pain due to osteoarthritis in a hip and/or knee joint.
- In October 2022, Eupraxia Pharmaceuticals Inc. announced updates to its Phase II trial, which is evaluating EP-104IAR's efficacy and safety for the treatment of osteoarthritis ("OA") of the knee.Eupraxia announced that its ongoing Phase II study has successfully completed all DSMB reviews, with no drug-related Serious Adverse Events noted and a clean safety profile.
Osteoarthritis Overview
Osteoarthritis (OA) is the most common form of arthritis, primarily affecting older adults but can also occur in younger individuals due to injury or other factors. It is a degenerative joint disease characterized by the breakdown of cartilage in the joints, leading to pain, stiffness, and reduced mobility. Risk factors include age, genetics, obesity, joint injury, and repetitive stress on the joints.
The hallmark feature of Osteoarthritis is the gradual loss of cartilage, which normally cushions the ends of bones and allows smooth joint movement. As cartilage deteriorates, bones may rub against each other, causing pain, swelling, and inflammation. Osteoarthritis commonly affects weight-bearing joints such as the knees, hips, spine, and hands.
Osteoarthritis Diagnosis is based on symptoms, physical examination, and imaging studies such as X-rays or MRI scans. Treatment aims to manage symptoms, improve joint function, and slow disease progression. This may include lifestyle modifications (e.g., exercise, weight management), physical therapy, pain relievers, corticosteroid injections, and in severe cases, joint replacement surgery.
Although Osteoarthritis is chronic and progressive, early diagnosis and intervention can help alleviate symptoms and improve quality of life. Research continues to explore new therapies and interventions to better manage this prevalent condition.
Learn more about Osteoarthritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Osteoarthritis Patient Pool Market Forecasting
Osteoarthritis Market
The Osteoarthritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Osteoarthritis market trends by analyzing the impact of current Osteoarthritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Osteoarthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Osteoarthritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The osteoarthritis market is primarily driven by the rising global prevalence of the disease, especially among the aging population, coupled with increasing obesity rates and sedentary lifestyles that contribute to joint degeneration. Advancements in treatment modalities—including regenerative medicine, intra-articular therapies, and novel drug delivery systems—are also fueling market growth.
Additionally, greater awareness, improved diagnostic tools, and ongoing research and development activities by pharmaceutical companies are expanding therapeutic options. However, the market faces significant barriers such as the high cost of advanced therapies, limited efficacy and side effects of current medications, and the lack of disease-modifying treatments. Regulatory hurdles, reimbursement challenges, and variability in treatment accessibility across regions further hinder market expansion.
According to DelveInsight, the Osteoarthritis market in 7MM is expected to witness a major change in the study period 2019-2034.
Osteoarthritis Epidemiology
The Osteoarthritis epidemiology section provides insights into the historical and current Osteoarthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Osteoarthritis market report also provides the diagnosed patient pool, trends, and assumptions.
Osteoarthritis Epidemiology Segmentation:
- Total Diagnosed Cases of Osteoarthritis
- Joint Site–Specific Prevalence of Osteoarthritis
- Gender-Specific Prevalence of Osteoarthritis
- Age-Specific Prevalence of Osteoarthritis
- Severity-Specific Prevalence of Osteoarthritis
Explore more about Osteoarthritis Epidemiology @ Osteoarthritis Market Dynamics and Trends
Osteoarthritis Drugs Uptake
This section focuses on the uptake rate of the potential Osteoarthritis drugs recently launched in the Osteoarthritis market or expected to be launched in 2019-2034. The analysis covers the Osteoarthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Osteoarthritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Osteoarthritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Osteoarthritis Pipeline Development Activities
The Osteoarthritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Osteoarthritis key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Osteoarthritis pipeline development activities @ Osteoarthritis Companies and Medication
Osteoarthritis Therapeutics Assessment
Major key companies are working proactively in the Osteoarthritis Therapeutics market to develop novel therapies which will drive the Osteoarthritis treatment markets in the upcoming years are Novartis (NVS:NYSE), Ampio Pharmaceuticals (AMPE:OTC), Taiwan Liposome Company (4152:TPEX), Centrexion Therapeutics, Biosplice Therapeutics, Organogenesis (ORGO:NASDAQ), Kolon TissueGene (950160:KQ), Paradigm Biopharma (PAR:ASX), Novo Nordisk (NVO:NYSE), Amzell, Nature Cell (007390:KQ), Tissuetech, Techfields Pharma (688221:SSE), Sorrento Therapeutics (SRNEQ:OTC), Merck KGaA (MRK:XETRA), Anika Therapeutics (ANIK:NASDAQ), TrialSpark, AKL Research and Development, Flexion Therapeutics (acquired by Pacira BioSciences), OliPass Corporation (244460:KQ), Pacira BioSciences (PCRX:NASDAQ), Medipost (078160:KQ), Medivir (MVIR-B:OMXSTO), among others.
Learn more about the emerging Osteoarthritis therapies & key companies @ Osteoarthritis Clinical Trials and FDA Approvals
Osteoarthritis Report Key Insights
1. Osteoarthritis Patient Population
2. Osteoarthritis Market Size and Trends
3. Key Cross Competition in the Osteoarthritis Market
4. Osteoarthritis Market Dynamics (Key Drivers and Barriers)
5. Osteoarthritis Market Opportunities
6. Osteoarthritis Therapeutic Approaches
7. Osteoarthritis Pipeline Analysis
8. Osteoarthritis Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Osteoarthritis Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Osteoarthritis Competitive Intelligence Analysis
4. Osteoarthritis Market Overview at a Glance
5. Osteoarthritis Disease Background and Overview
6. Osteoarthritis Patient Journey
7. Osteoarthritis Epidemiology and Patient Population
8. Osteoarthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Osteoarthritis Unmet Needs
10. Key Endpoints of Osteoarthritis Treatment
11. Osteoarthritis Marketed Products
12. Osteoarthritis Emerging Therapies
13. Osteoarthritis Seven Major Market Analysis
14. Attribute Analysis
15. Osteoarthritis Market Outlook (7 major markets)
16. Osteoarthritis Access and Reimbursement Overview
17. KOL Views on the Osteoarthritis Market
18. Osteoarthritis Market Drivers
19. Osteoarthritis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
